FOLD News and Press, Amicus Therapeutics Inc. From 05/08/19

Amicus Therapeutics ( FOLD ) Q1 results : Revenues: $34.1M (+104.2%). More news on: Amicus Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...

Amicus Therapeutics (NASDAQ: FOLD ): Q1 GAAP EPS of -$0.56 misses by $0.26 . More news on: Amicus Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

1Q19 Galafold ® (m igalastat) Strong Launch Trends Continue with Largest Quarterly Number of Net New Patients Added Globally (150+ Net New Galafold Patients in 1Q19) 1Q19 Galafold Revenue of $34.0M and Early 2Q19 Momentum on Key Launch Metrics Maintaining F...

ACM , ANDX , ATHM , ATRO , BCOR , BG , BV , CBB , CBRE , CEIX , CFX , CHK , CORE , COTY , FOLD , FTDR , FUN , GCP , GOLD , GOLF , GTN , GTT , HMC , HZNP , ICPT , LXP , MCHP , MCK , MIDD , MPC , MPLX , MRNA , MSG , NXST , NYT , ODP , PFGC , PLUG , PTLA ...

The following slide deck was published by Amicus Therapeutics, Inc. in conjunction with this Read more ...

Preclinical Studies Show Robust Uptake and Glycogen Reduction in Multiple Tissues, Including Brain and Spinal Cord Initial Validation for Collaboration Combining Amicus-Engineered Transgenes with Penn’s AAV Gene Therapy Technologies Significant and Broad New Amicus Pla...

Noteworthy events during the week of April 28 - May 4 for healthcare investors. More news on: Catalyst Biosciences, Inc., Aldeyra Therapeutics, Inc., BioTime, Inc., Healthcare stocks news, , Read more ...

CRANBURY, N.J., April 25, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 8, 2019 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2019. The...

Amicus Therapeutics ( FOLD ) has significantly transformed over the last few years. From a company with an uncertain regulatory status of its lead product (Galafold) and a young and not too diversified pipeline to a company with substantial evidence of strong commercial capabilities and a si...

CRANBURY, N.J., April 15, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the company will present initial preclinical data from its investigational adeno-associated viral (AAV) gene therapy program for Pompe disease in a poster at the American Society of Gene ...